Atlas Trials

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Clinical trial NCT04468984 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04468984
Sponsor
AbbVie
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Myelofibrosis (MF)
Start date
2020-08-31
Primary completion
2025-01-29
Enrollment
330

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.